FY2029 Earnings Forecast for AVTE Issued By Wedbush

Aerovate Therapeutics, Inc. (NASDAQ:AVTE) – Wedbush issued their FY2029 earnings estimates for Aerovate Therapeutics in a report released on Monday, February 24th. Wedbush analyst L. Chico anticipates that the company will post earnings per share of ($0.74) for the year. The consensus estimate for Aerovate Therapeutics’ current full-year earnings is ($2.64) per share.

Aerovate Therapeutics Price Performance

NASDAQ AVTE opened at $2.42 on Wednesday. The company has a market cap of $69.88 million, a price-to-earnings ratio of -0.81 and a beta of 0.99. The stock’s fifty day moving average price is $2.54 and its 200 day moving average price is $2.34. Aerovate Therapeutics has a 1 year low of $1.25 and a 1 year high of $32.42.

Institutional Trading of Aerovate Therapeutics

Several large investors have recently added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in shares of Aerovate Therapeutics by 226.8% in the third quarter. GSA Capital Partners LLP now owns 413,795 shares of the company’s stock worth $865,000 after purchasing an additional 287,163 shares during the last quarter. FMR LLC increased its holdings in Aerovate Therapeutics by 54,095.4% in the 3rd quarter. FMR LLC now owns 82,919 shares of the company’s stock worth $173,000 after buying an additional 82,766 shares during the period. State Street Corp raised its position in Aerovate Therapeutics by 7.7% during the 3rd quarter. State Street Corp now owns 367,468 shares of the company’s stock worth $768,000 after buying an additional 26,278 shares during the last quarter. Barclays PLC lifted its stake in Aerovate Therapeutics by 310.8% during the 3rd quarter. Barclays PLC now owns 18,972 shares of the company’s stock valued at $39,000 after acquiring an additional 14,354 shares during the period. Finally, FNY Investment Advisers LLC acquired a new stake in Aerovate Therapeutics during the 4th quarter valued at approximately $198,000.

Aerovate Therapeutics Company Profile

Aerovate Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops drugs that enhance the lives of patients with rare cardiopulmonary diseases in the United States. It focuses on advancing AV-101, a dry powder inhaled formulation of imatinib for the treatment of pulmonary arterial hypertension, which is in Phase 2b/Phase 3 trial.